Cartesian Therapeutics (NASDAQ:RNAC) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Cartesian Therapeutics (RNAC) operate in?

Cartesian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cartesian Therapeutics Stock (NASDAQ: RNAC) stock price, news, charts, stock research, profile.

Open	$19.98
Close	$19.24
Volume / Avg.	54.85K / 103.52K
Day Range	$19.22 - $19.98
52 Wk Range	11.67 - 41.87
Market Cap	$494.95M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	51
Short Interest	12.11%
Days to Cover	28.13

Recent News

Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family

Avi Kapoor

Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M

Cartesian Therapeutics reported Phase 2b trial results for Descartes-08 in generalized myasthenia gravis, showing significant improvements in MG Composite scores with a favorable safety profile. The therapy achieved its primary endpoints.

Vandana Singh

What Makes Cartesian Therapeutics, Inc. a New Buy Stock

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Sep 24

Oct 24

Nov 24

Dec 24

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$19.98
Close	$19.24
Volume / Avg.	54.85K / 103.52K
Day Range	$19.22 - $19.98
52 Wk Range	11.67 - 41.87
Market Cap	$494.95M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	51
Short Interest	12.11%
Days to Cover	28.13

About Cartesian Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTO...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cartesian Therapeutics (RNAC) stock?

You can purchase shares of Cartesian Therapeutics (NASDAQ:RNAC) through any online brokerage.

View our list of the best stock brokerages

Who are Cartesian Therapeutics (RNAC) competitors?

Other companies in Cartesian Therapeutics’s space includes: Tectonic Therapeutic (NASDAQ:TECX), KalVista Pharma (NASDAQ:KALV), Humacyte (NASDAQ:HUMA), Precigen (NASDAQ:PGEN) and Celcuity (NASDAQ:CELC).

What is the forecast, or price target, for Cartesian Therapeutics (RNAC) stock?

Cartesian Therapeutics has a consensus price target of $41.67.

What is the current price for Cartesian Therapeutics (RNAC)?

The stock price for Cartesian Therapeutics (NASDAQ: RNAC) is $19.24 last updated February 21, 2025 at 4:00 PM EST.

Does Cartesian Therapeutics (RNAC) pay a dividend?

There are no upcoming dividends for Cartesian Therapeutics.

When is Cartesian Therapeutics (NASDAQ:RNAC) reporting earnings?

Cartesian Therapeutics’s Q1 earnings are confirmed for Wednesday, May 7, 2025.

Is Cartesian Therapeutics (RNAC) going to split?

There is no upcoming split for Cartesian Therapeutics.

What sector and industry does Cartesian Therapeutics (RNAC) operate in?

Cartesian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Cartesian Therapeutics

Cartesian Therapeutics (RNAC) Forecast